BioSpace News Archive

Rocket Pharmaceuticals, Inc. announces that the first patient has received investigational therapy in the open-label, Phase 1 clinical trial of RP-L301, the Company’s lentiviral vector -based gene therapy for the treatment of Pyruvate Kinase Deficiency, a rare monogenic red blood cell disorder.

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it has successfully completed the Container Closure Integrity test that is required by the U.S. Food and Drug Administration for its CypCaps™ product and has passed the FDA-required test.

The approved projects involve innovations in the areas of Automotive, Cyber Security, Healthcare IT, Homeland Security, Life Sciences, and others

Aquarius Surgical Technologies Inc. is moving forward with new laser and fiber sales as ASTI’s minimally invasive surgeries have been classified as essential procedures, specifically for patients who have issues associated with potential kidney failure or urinary retention.

Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will be presenting virtually at the upcoming Zooming with LD event on Thursday, July 23rd at 11:00 AM ET.

Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 Introducing HADUVIO ™ as Proposed Trade Name for Nalbuphine ER

Kainomyx, Inc., founded in September 2019 and financed with $7.5 Million in May 2020, today announced launch of its programs to address malaria and other parasitic diseases.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is participating in the launch of Kainomyx, Inc., a new biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of parasitic diseases. Under the terms of the agreement, Cytokinetics will transfer certain compounds identified at Cytokinetics to be selective inhibitors of a cytoskeletal protein in parasites

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”) today announces it plans to issue its fiscal first quarter 2020 earnings press release on Tuesday, July 14, 2020, after U.S. markets close, commensurate with the filing of its unaudited financial results

Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020. The NuProtect study (NCT01712438) investigated the immunogenicity, efficacy and safety of Nuwiq ® (simoctocog alfa) in 108 previously untreated patients with haemophilia A. The final re